Software as a Medical Device & Patient companion apps

Huma builds regulated Software as a Medical Device (SaMD) solutions

Building a SaMD is complex. Launching it across several continents is even more challenging, but the hardest part is scaling and sustaining it across thousands of hospitals, clinics and patients. When you see our technology, infrastructure and innovation in operation, you will understand why some of the world's biggest life science companies have chosen to use Huma.

Talk to us

Winner of the 2022 Prix Galien International award for digital health, 'pharma's Nobel prize'1

1.0m+

Active users across
our platforms2

90-90%

Adherence and retention rates across our care and research deployments3

0m+

Devices have been shipped in support of our projects2

0+

Hospitals and clinics use our technologies to make sustainable impacts for patients2

Global scale

Huma's digital-first health platforms support a network of 27m patients2

  • samd solutions
  • market success
  • improving patient outcomes

Launching your
SaMD solutions

We advance connected care, helping you build and scale complex SaMD digital companions that are intuitive to use and eagerly adopted.

Our experienced team of Engineers, Designers, Clinicians and Project Managers can rapidly launch and sustain bespoke products with our device, disease and cloud agnostic platform.

Modular or bespoke

SDKs

Full Quality & Regulatory compliance

Leading data security and privacy standards

Experienced regulatory team

Track record to deploy at scale

Adherence and user engagement

Data science capabilities

Dedicated teams

Assist go-to-market and commercialisation

Speed your way to
market success

Ready-to-deploy, proven modules

Secure, scalable, and fully compliant: our platform accelerates time to market for regulated digital health products — including companion apps, patient support and engagement programs.

Our ready-to-deploy modules include:

Onboarding

Timeline and notifications

Questionnaires

Carers and proxies

Telemedicine⁴

Connected devices

Seamless interoperability

Analytics dashboards

Behaviour change

Mental health support

Call centre⁴

Improving patient outcomes

Enable clinical oversight for prevention and early diagnosis

Patient support and engagement

Optimise disease management

Increase adherence

Learn from every case

Generate real world data

Transforming
healthcare

Registered and able to immediately place products in 33 countries.

Capable of supporting all language requirements.

Self-service modular platform to enable rapid configuration.

"The Most Important Healthcare Design of 2021" by Fast Company

Industry-leading and flexible IoMT integration

We are certified under ISO 27001, Cyber Essentials Plus and we are 21 CFR and GxP compliant

Cloud-agnostic platform that can run on any system

Can be deployed across multiple therapeutic areas

Orthopaedics,
Diabetes, Heart
health

Care team revieving report.

Connect with us and our partners

We have successfully deployed some of the largest SaMD solutions across multiple patient populations, including heart failure, cardio metabolic disease, pulmonary hypertension and more.

Compliance built-in

EU MDD & MDR

ISO13485

ISO27001

21CFR820 US FDA Class I exempt

IEC/ISO62304

IEC 82304-1

ISO14971

ISO14155

IEC62366

CyberEssentials

CyberEssentials Plus

Approved Pharma Supplier

Regulatory Intelligence

Global Regulatory Footprint

World-leading healthcare
companies partner
with Huma

Logos of Huma's partners. Logos of Huma's partners.

Talk to us

This field is required

This field is required

This field is required

This field is required

This field is required

Country/Region*
United Kingdom
United States
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, The Democratic Republic of the
Cook Islands
Costa Rica
Cote D"Ivoire
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and Mcdonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic Of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People"S Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People"S Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libyan Arab Jamahiriya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, The Former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russian Federation
RWANDA
Saint Helena
Saint Kitts and Nevis
Saint Lucia
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe

This field is required

I'm interested in
Companion app for Pharmaceutical companies
Companion app for MedTech companies
Decentralised Clinical Trials (DCT)
Hospital @ Home
Software as a Medical Device (SaMD)
Partnering with Huma
Other

This field is required

Huma is committed to respecting your privacy, and we’ll only use your personal details to provide information you have selected you’re interested in. Review our Privacy Policy for further information.

We’d love to send you our monthly newsletter about our latest work, research and events by email. We’ll always treat your personal details with the utmost care and will never sell them to other companies for marketing purposes.

You’re in control. You can, of course, withdraw your consent at any time. Review our Privacy Policy for further information.

Success message with thumbs up for filling out the form.
Thank you for requesting the Huma SaMD fact sheet!
There was an error submitting your form. Please refresh and try again.

Sources

1. Winner of the 2022 Prix Galien International and 2021 Prix Galien USA awards for digital health https://huma.com/announcement/huma-prix-galien-2022

2. Based on internal data, correct as of June 2022

3. Range of data from across a number of Huma projects

4. The telemedicine and call centre functionality is used through the app but is not part of the medical device.

5. https://www.nhsx.nhs.uk/covid-19-response... The full report is available on request.

6. Data from 2021 pilot study. Full evaluation of the service is in preparation

7. Dolezalova, N et al. (2021) Development of an accessible 10-year Digital CArdioVAscular (DiCAVA) risk assessment: a UK Biobank study, European Heart Journal Digital Health https://doi.org/10.1093/ehjdh/ztab057

8. Publication in production

Cookie settings